Atossa Therapeutics Inc. (NASDAQ: ATOS) Stock Information | RedChip

Atossa Therapeutics Inc. (NASDAQ: ATOS) Listen to this Section


$1.28
+0.0400 ( +3.23% ) 795.7K

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Market Data


Open


$1.28

Previous close


$1.24

Volume


795.7K

Market cap


$160.97M

Day range


$1.25 - $1.32

52 week range


$0.62 - $2.31

Insider Ownership Transactions

Total Amount Purchased: -3,118,634.00 | $ -3,991,851.52

Date Type Amount Purchased Purchaser
2024-07-01 Sale -577700.00 Rees Heather
2024-07-01 Sale -125000.00 Cigler Tessa
2024-07-01 Sale -125000.00 Galli Stephen J
2024-07-01 Sale -1795100.00 QUAY STEVEN C
2024-07-01 Sale -125000.00 Finn Jonathan
2024-07-01 Sale -125000.00 Chen Shu-Chih
2024-07-01 Sale -125000.00 Remmel H. Lawrence
2024-07-01 Sale -125000.00 Steinhart Richard I
2024-04-11 Buy 25000.00 Finn Jonathan
2024-03-14 Sale -20834.00 Cigler Tessa

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 13 Aug 12, 2024
10-q Quarterly Reports 65 Aug 12, 2024
8-k 8K-related 13 Jul 02, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.